Clinical experience and diagnostic algorithm of vulval Crohn's disease

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):838-843. doi: 10.1097/MEG.0000000000000879.

Abstract

Background and aim: Vulval Crohn's disease (VCD) is a rare extraintestinal cutaneous manifestation of Crohn's disease. No consensus on the diagnostic workup and therapeutic management of this condition has been provided in the current literature.

Patients and methods: Retrospective, multicentre descriptive case series of female patients diagnosed and treated with VCD. By chart review, data on initial symptoms, clinical courses, histologic findings and therapeutic management were collected.

Results: Fifteen female patients with a median age of 28 years (interquartile range: 28-44 years) suffering from Crohn's disease of the ileum (27%), colon (33%) and ileocolon (40%) were included. VCD manifested most frequently with vulval swelling (93%), pain (80%) and erythema (73%). Histologic analysis demonstrated granulomatous inflammation in 78% and a mixed inflammatory cell infiltrate in 67% of cases. In eight (53%) cases, topical therapy resulted in temporary reduction of vulval symptoms. Combotreatment with immunosuppressive agents and tumour necrosis factor α inhibitors was the most effective second-line therapy: five (33%) patients achieved sustained clinical remission with this therapeutic strategy.

Conclusion: The diagnostic workup of VCD is challenging and should be approached in a multidisciplinary manner. Histopathologic analysis of the vulva supports the diagnosis. Topical therapy and systemic treatment with immunosuppressive agents and tumour necrosis factor α inhibitors are advised to treat this condition.

Publication types

  • Multicenter Study

MeSH terms

  • Administration, Topical
  • Adult
  • Algorithms*
  • Biological Products / administration & dosage*
  • Biological Products / adverse effects
  • Critical Pathways*
  • Crohn Disease / diagnosis*
  • Crohn Disease / drug therapy*
  • Databases, Factual
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Immunosuppressive Agents / adverse effects
  • Netherlands
  • Patient Care Team
  • Predictive Value of Tests
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Vulvar Diseases / diagnosis*
  • Vulvar Diseases / drug therapy*

Substances

  • Biological Products
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha